Clinical Snippets  by unknown
1708 Journal of Investigative Dermatology (2015), Volume 135 © 2015 The Society for Investigative Dermatology
clinical snippets
Atrophy Arrest 
a significant problem with the 
use of glucocorticoids (Gcs), 
such as clobetasol, to treat 
chronic inflammatory skin dis-
eases is the accompanying skin 
atrophy. Maubec and colleagues 
demonstrated that blockade of 
the mineralocorticoid receptor 
(MR), which is activated by Gcs 
in the epidermis, limits clobeta-
sol-induced epidermal atrophy 
and impaired keratinocyte 
proliferation. in a randomized 
double-blind phase ii clinical 
trial, topical treatment with the 
classic MR blocker spironolac-
tone, which has proven safe for 
treating hypertension and car-
diac failure, led to improvement 
in Gc-induced skin atrophy, 
endorsing the clinical relevance 
of these findings. See page 1781
Mapping Methylation 
Minefields
a subset of melanomas with 
increased cpG island meth-
ylation has been described, 
although other genes are 
hypomethylated and thereby 
activated. lauss and colleagues 
investigated the epigenetic 
landscape of melanoma using 
high-density genome-wide 
arrays for 480,000 cpGs in 50 
metastatic melanoma tumors. in 
combination with gene expres-
sion data, these studies revealed 
that the master regulator of 
pigmentation, the MITF gene, as 
well as MITF target genes, were 
regulated by hypermethylation. 
Demethylation of cell lines with 
hypermethylated MITF induced 
MitF pathway activity, confirm-
ing control by demethylation 
and offering insight into the 
development of melanoma. See 
page 1820
Age Marks the Spot
Although candidate gene studies have 
shed some light on gene variants associ-
ated with the facial pigmented spots that 
are part of the complex skin aging phe-
notype, Jacobs and colleagues sought to 
explore this issue using a genome-wide 
association study of 2,844 Dutch indi-
viduals. DNA variants in IRF4, MC1R, 
ASIP, and BNC2 were significantly asso-
ciated with facial pigmented spots, and this association was independent of age, sex, 
and skin color. Following confirmation of these results in an additional cohort, the 
investigators concluded that these genetic variations contribute to the development 
of facial pigmented spots during aging via pathways independent of basal melanin 
 production. See page 1735
Ligand-Fueled Resistance
Acquired resistance to BRAF inhibitors, 
such as vemurafenib, used for the treat-
ment of BRAF-mutant melanomas has 
plagued clinical success. Activation of 
receptor tyrosine kinases has been impli-
cated in this resistance. Using compara-
tive molecular studies, Ji and colleagues 
demonstrated that loss of the master 
melanocyte lineage regulator microph-
thalmia-associated transcription factor (MITF) potentiates an EGFR autocrine resis-
tance loop, thus mediating drug resistance. A reciprocal relationship between MITF 
and EGFR was observed in melanoma clinical samples and correlated with vemu-
rafenib response. Because these results implicate the presence of ligand in this resis-
tance, EGFR levels are not a suitable clinical biomarker for vemurafenib resistance. 
See page 1863
Google Earth for Skin
Sokol and colleagues employed nanoto-
my based on large-scale electron micros-
copy, which, similar to Google Earth, 
allows users to examine tissue at differ-
ent levels—from a complete overview 
to in-depth analysis at macromolecular 
resolution—in order to study the patho-
physiology of pemphigus in human 
patients. These data offer insight into the 
currently unclear mechanism by which autoantibodies to desmogleins evoke acan-
tholysis in pemphigus patients. Most important, this unbiased approach and sharing 
of electron microscopy data allow easy analysis of vast ultrastructural images and 
will undoubtedly facilitate interdisciplinary research for human disease in the future. 
See page 1763
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